Acquired Amegakaryocytic Thrombocytopenia Progressing to Aplastic Anaemia
Department
Internal Medicine
Document Type
Article
Publication Title
European Journal of Case Reports in Internal Medicine
Abstract
Acquired amegakaryocytic thrombocytopenia (AAMT) is a rare disorder of the bone marrow characterized by a lack of megakaryocytes and preservation of other cell lines. It can occur due to an intrinsic stem cell defect or secondary to viral infections, autoimmune disorders, lymphoproliferative disorders or environmental toxins. With time, it can progress to aplastic anaemia (AA) and can have a poor prognosis. No standard guidelines exist for the treatment of AAMT progressing to AA. Herein, we report a rare case of AAMT leading to AA and review the handful of cases previously published in the literature.
Learning points: Acquired amegakaryocytic thrombocytopenia can present as isolated severe thrombocytopenia which can initially be misdiagnosed as immune thrombocytopenia.Lack of response to steroids and intravenous immunoglobulin should raise suspicion for acquired amegakaryocytic thrombocytopenia.Over time, acquired amegakaryocytic thrombocytopenia can progress to aplastic anaemia, which confers a worse prognosis.
First Page
003479
DOI
10.12890/2022_003479
Volume
9
Issue
9
Publication Date
9-5-2022
PubMed ID
36299833
Recommended Citation
Hussain, S. A., Fatima, H., Faisal, H., & Bansal, M. (2022). Acquired Amegakaryocytic Thrombocytopenia Progressing to Aplastic Anaemia. European Journal of Case Reports in Internal Medicine, 9 (9), 003479. https://doi.org/10.12890/2022_003479